<p>Clinical results of intensity-modulated radiotherapy for 250 patients with cervical and upper thoracic esophageal carcinoma</p>

Abstract

PurposeTo evaluate and analyze the efficacy and prognostic factors of intensity-modulated radiotherapy in 250 patients with cervical and upper esophageal carcinoma.Patients and methodsFrom September 2009 to September 2016, we retrospectively analyzed 250 patients with cervical and upper esophageal carcinoma treated with intensity-modulated radiotherapy (IMRT). In our study, all patients received IMRT, 54 patients with cervical esophageal carcinoma and 196 patients with upper esophageal carcinoma. Treatment response, survival status and failure modes of treatment were observed, and prognostic factors were analyzed.ResultsThe median survival time was 22.60 months and 3-year survival rate was 42%. The median progress-free survival time was 14.52 months and 3-year progress-free survival rate was 29.3%. The median survival time and the median progress-free survival time for cervical esophageal carcinoma were 20.40 and 15.15 months, respectively. The median survival time and the median progress-free survival time for upper esophageal carcinoma were 25.80 and 14.52 months, respectively (P>0.05). The significant clinical factors associated with survival were patient age, radiotherapy dose and T stages (P<0.05). Radiotherapy dose and concurrent chemoradiotherapy were the significant clinical factors related to progression-free survival (P<0.05). Recurrence appeared in 55.2% patients, including local recurrence in 22.40%, region relapse in 10.40% and distant metastasis in 12.40%. Local recurrence was the main mode of treatment failure. During treatment, the main treatment-related acute toxicity was leukocytopenia and anemia.ConclusionIn this study, IMRT demonstrated clinical benefit and well-tolerated toxicity in patients with cervical and upper esophageal carcinoma.

Dose Escalation in Radical Radio(chemo)therapy for Cervical and Upper Thoracic Esophageal Cancer with 3DCRT/IMRT (ChC&amp;UES): A Multi-center Real world Study

“…and Partial Response (PR) rate 29 , aligning with the results of our study. Nevertheless, in the context of upper thoracic ESCA, ORR did not translate into improved survival.…”

The Application of Nimotuzumab Combined With Definitive Chemoradiotherapy Toward the Treatment of Locally Advanced Cervical Esophageal Carcinoma: A Retrospective Study

“…They also proposed that some patients with residual tumor in dCRT group who underwent salvage surgery achieved a similar 5-year survival rate as those in the surgery group. Furthermore, several studies have looked into the advantages of IMRT in CEC (26)(27)(28). Compared with 2D-RT and 3D conformal RT, IMRT combined with concurrent chemotherapy had reduced incidence of late toxicity and accomplished better OS rate (9,29).…”

Long-term survival of an unresectable upper thoracic esophageal squamous cell carcinoma with severe dysphagia following nasogastric tube feeding and camrelizumab-containing therapy: a case report

“…Therefore, chemoradiotherapy, radiotherapy, and chemotherapy have been frequently performed in upper thoracic ESCC. However, the overall prognosis is poor ( 3 , 4 ). Therefore, exploring other effective and safe treatment is of great importance.…”